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ABSTRACT
P-glycoprotein (P-gp) is a key player in the multidrug-resistant
phenotype in cancer. The protein confers resistance by mediating
the ATP-dependent efflux of an astonishing array of anticancer drugs.
Its broad specificity has been the subject of numerous attempts to
inhibit the protein and restore the efficacy of anticancer drugs.
The general strategy has been to develop compounds that either
compete with anticancer drugs for transport or act as direct
inhibitors of P-gp. Despite considerable in vitro success, there are no
compounds currently available to “block” P-gp–mediated resistance
in the clinic. The failure may be attributed to toxicity, adverse drug
interaction, and numerous pharmacokinetic issues. This review
provides a description of several alternative approaches to over-
come the activity of P-gp in drug-resistant cells. These include 1)
drugs that specifically target resistant cells, 2) novel nanotechnol-
ogies to provide high-dose, targeted delivery of anticancer drugs, 3)
compounds that interfere with nongenomic transfer of resistance,
and 4) approaches to reduce the expression of P-gp within tumors.
Such approaches have been developed through the pursuit of
greater understanding of resistance mediators such as P-gp, and
they show considerable potential for further application.
Introduction
The “permeability glycoprotein” or P-glycoprotein (P-gp or ABCB1)
was discovered in 1976 in rodent cells known to display reduced sen-
sitivity to anticancer drugs (Juliano and Ling, 1976). It was soon dem-
onstrated that selection of cultured cancer cell lines in chemotherapeutic
drugs displayed a phenotype consistent with the presence of P-gp.
Moreover, these drug-resistant cell lines displayed resistance to a large
number of chemically, structurally, and functionally unrelated drugs;
hence the moniker of “multidrug resistance” (MDR). By the 1980s,
antibodies had been developed to P-gp, and it was revealed that the
protein was expressed in many distinct types of cancer as well as
numerous normal tissues (Kartner et al., 1985; Cordon-Cardo et al.,
1989, 1990).
The overexpression of P-gp in cancer was either an inherent or
acquired process: the former, a reflection of its physiologic expression,
and the latter, generated by the presence of anticancer drugs. P-gp
confers resistance by preventing sufficient accumulation of anticancer
drugs within the cell, thereby avoiding their cytotoxic or apoptotic
effects. This is achieved by its ability to mediate ATP-dependent drug
translocation across the plasma membrane against considerable con-
centration gradients. P-gp is a member of the B-class of the eukaryotic
ATP binding cassette (ABC) superfamily of transporters. Its influence
in conferring MDR was at one time considered the paramount factor
in the phenotype (Steinbach and Legrand, 2007). However, the
burgeoning biochemical characterization of cancer cells revealed that
the protein is a member of a network of cellular factors or tissue
features that produce drug resistance (Mellor and Callaghan, 2008).
The influence of P-gp was apparently further diluted by the discovery
of two other ABC proteins able to confer MDR, namely, MRP1 (ABCC1)
and BCRP (ABCG2) (Cole et al., 1992; Doyle et al., 1998). It is worth
noting that although all three mediate active drug extrusion, their
substrate specificities and expression patterns in cancer are distinct but
with some overlap. The present review will focus on the role of P-gp
and attempts to overcome its unwanted influence in cancer.
The multiplicity of factors contributing to drug resistance and the
inability to overcome the actions of P-gp and restore the sensitivity of
chemotherapy have led to researchers questioning its very involvement
in clinical resistance (Bradshaw and Arceci, 1998; Merino et al., 2004;
Perez-Tomas, 2006). This clear overreaction should be tempered by the
plethora of investigations that have described the association of P-gp
with drug resistance and the positive relationship between expression
and poor prognosis (Gottesman et al., 2002; Leonard et al., 2003;
Modok et al., 2006; Shaffer et al., 2012). The present review will not
further discuss the relative merit or influence of P-gp in drug resistance
but concentrate on efforts to overcome its actions.
Originally, it was thought that the actions of P-gp were limited to
conferring resistance to classic genotoxic anticancer drugs, such as
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vinblastine, doxorubicin, and paclitaxel. The broad or polyspecificity
of P-gp is legendary (or infamous), and the list of compounds known
to interact with this transporter is well in excess of 300 (Wang et al.,
2011; Chen et al., 2012). It is apparent that many of the much touted
“new generation” anticancer compounds (e.g., kinase inhibitors) are
also substrates for transport by P-gp (Hegedus et al., 2002; Wang and
Fu, 2010). There is a clear need to generate compounds, or strategies,
to overcome the actions of P-gp in 1) limiting the effectiveness of
chemotherapy in cancer and 2) influencing the pharmacokinetic pro-
file of a vast number of clinically prescribed drugs.
Overcoming Drug Resistance to Chemotherapy Caused by P-gp
The general strategy to overcome multidrug resistance has been to
coadminister chemical inhibitors of P-gp with anticancer drugs.
Inhibition of P-gp would thereby lead to increased accumulation of
anticancer drug within the cell and produce cell cytotoxicity. Al-
ternatively, addition of a P-gp substrate in conjunction with the
anticancer drug would achieve a similar effect by competing for the
transport process. The first inhibitor (or more correctly referred to as
a P-gp modulator) identified was the L-type calcium channel blocker
verapamil (Tsuruo et al., 1982, 1983). This drug was shown to
circumvent MDR using a variety of cell cytotoxicity, transport,
binding, and photolabeling assays (Cornwell et al., 1987; Safa, 1988).
However, clinical trials with verapamil were beset by serious cardiac
side effects, and the compound was removed as a viable option (Ozols
et al., 1987; Dalton et al., 1989). Verapamil inhibits L-type calcium
channels with picomolar affinity; however, the potency to block P-gp
was in the micromolar range, a 106 higher concentration.
In the ensuing 30 years, three distinct generations of P-gp modulator
have been produced, and unfortunately a clinically useable inhibitor
remains elusive (McHugh and Callaghan, 2008; Crowley et al., 2010).
The first generation of compound used drugs with established and
unrelated pharmacological actions and relied on the polyspecificity of
P-gp. The next generation employed chemically modified first
generation inhibitors. Ideally, these compounds were devoid of the
parent compound’s activity while retaining (or improving) the potency
of interaction with P-gp. The third generation produced inhibitors
from de novo synthesis using a variety of combinatorial chemistry
approaches and benefiting from the burgeoning database of structure-
activity relationships for drug–P-gp interaction.
A large number of compounds have been examined, and several
recurring themes have emerged from their preclinical and clinical
characterization. The first two generations were beset with poor
potency of the compounds and a number of “off-target effects” that
resulted in problems with toxicity (Gottesman et al., 2002; McHugh
and Callaghan, 2008).
The third generation of P-gp modulators was frequently associated
with adverse drug reactions that necessitated a reduction in the dose of
anticancer agents. Many of the adverse drug interactions are related to
the overlapping substrate specificity between P-gp and the drug me-
tabolizing enzyme cytochrome P450 (CYP3A4 isoform) (Wacher
et al., 1995; Yu, 1999). The combined effects of these two “defender
proteins” will influence the absorption, distribution, metabolism, and
elimination of a large proportion of known medications. Therefore, the
coadministration of two drugs (i.e., modulator and anticancer drug)
that interact with both P-gp and CYP3A4 often generates unpredict-
able toxicity related to the emergence of unwanted pharmacokinetic
parameters. Such issues with pharmacokinetic profiles have resulted in
the apparent downfall of potent P-gp inhibitors, such as Tariquidar
(Pusztai et al., 2005). The fall from grace of this leading P-gp inhibitor
led to considerable pessimism regarding the validity of utilizing efflux
pump inhibition as a means to overcome drug resistance. However,
more recent observations have demonstrated that the coadministration
of Tariquidar with Vinorelbine (Abraham et al., 2009) did not produce
a similar toxicity profile as demonstrated with doxorubicin/docetaxel
(Pusztai et al., 2005). Moreover, a structure-activity investigation has
produced derivatives of Tariquidar with near negligible ability to
interact with CYP3A4, while retaining P-gp inhibition (Labrie et al.,
2007). These observations provide an argument for the retention of
this strategy.
The presence of “endogenous or physiological” P-gp has also be-
come problematic to the chemical inhibition strategy. P-gp is ex-
pressed at barrier tissue to sanctuary sites (e.g., blood-brain barrier)
and at secretory/absorptive tissues (e.g., gastrointestinal tract) (Cordon-
Cardo et al., 1989, 1990). The protein acts as a cellular defender and
is involved in establishing the overall pharmacokinetic profile for
numerous drugs. Unfortunately, chemical inhibitors are not capable
of discriminating between P-gp expressed at normal sites in the body
and that found in cancerous tissue. Therefore, the strategy generates
unwanted side effects at a number of nontumor sites in the body, for
example, increased permeability at the blood-brain barrier. Increased
penetration, or distribution, of genotoxic anticancer drugs into the
brain is associated with a severe toxicity profile that necessitates dose
reduction.
Novel Approaches to Overcoming the Actions of P-gp
The preceding sections indicated a significant role for P-gp in
conferring MDR to genotoxic anticancer drugs and many novel, target
specific cytostatic compounds. The controversy surrounding the
quantitative extent of its role in solid tumors cannot overshadow its
involvement. Moreover, the importance of chemotherapy as a primary,
adjuvant, or palliative treatment in cancer remains considerable and
thus justifies the need to overcome, or evade, the influence of P-gp.
Unfortunately, the strategy of developing potent and selective
compounds to inhibit P-gp and overcome resistance has encountered
a number of issues. The issues relate to toxicity, dose reduction of
anticancer drugs, and perturbation of key barrier tissues. In recent
years there is a general pessimism by the pharmaceutical sector and
research funding bodies despite the consistent and demonstrable
improvements in design of inhibitors. There are also numerous
epiphenomena related to P-gp expression that offer the prospect of
therapeutic intervention. In this review we briefly describe some of the
novel approaches rooted in academic research to counter, or over-
come, the phenomenon of P-gp–mediated drug resistance.
Collateral Sensitivity
The emergence of a drug-resistant phenotype may be considered the
product of the influence of a number of environmental stress factors.
Typically, this will involve altered patterns of gene expression to
enable survival of the cancer cell. A large number of cultured cell lines
have been rendered drug resistant by prolonged exposure to certain
anticancer drugs, and they undoubtedly contain modified expression
patterns for numerous resistance mediators or enablers. The advent of
high-throughput proteomic analyses revealed that drug-resistant cells
or tumors display considerably modified protein expression profiles
(Righetti et al., 2005; Peng et al., 2010). For example, in a taxol-
resistant A2780 ovarian cancer cell line, proteomic analysis revealed
marked changes in stress response effectors, cell cycle, and apoptotic
mediators and numerous alterations in pathways for bioenergetic
metabolism (Cicchillitti et al., 2009). Any proteomic alterations that
are specific to drug-resistant cancer cells may, therefore, provide a
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target for potential therapeutic management. In acquiring a drug-
resistant phenotype, cancer cells may unwittingly proffer targets for
their own eradication.
Increased or even hypersensitivity of resistant cells to various drugs
was first observed in bacterial cells in the early 1950s (Szybalski and
Bryson, 1952). The phenomenon was referred to as collateral sen-
sitivity and was promoted a decade later for improving the efficacy of
anticancer drugs in combination chemotherapy (Paigen, 1962). In the
1980s a multitude of studies demonstrated improved efficacy of
methotrexate (Herman et al., 1979), folate analogs (Diddens et al.,
1983), and DNA alkylating drugs (Sladek et al., 1985) in the presence
of collateral sensitizing compounds. Unfortunately, the majority of
these studies were not able to provide a description of the underlying
resistant phenotype. A study in 1985 (Gupta, 1985) demonstrated
collateral sensitivity between a spectrum of anticancer drugs in
Chinese hamster ovary (CHO) cells that were eventually shown to
express high levels of P-gp. Subsequently, in 1987, Cano-Gauci and
Riordan provided the first demonstration that P-gp modulators
(i.e., calcium channel blockers) preferentially inhibited the growth of
drug-resistant cell lines.
It appears that the phenomenon of collateral sensitivity is closely
associated with all three of the multidrug ABC pumps expressed in
cancer cells (Oguro et al., 1990; Jensen et al., 1992). The precise
mechanism underlying collateral sensitivity remains unresolved, with
many hypotheses presented. As efforts in the 1990s to purify
functional P-gp began in earnest it was widely demonstrated that
resistant cells were more susceptible to procedures (e.g., nitrogen
cavitation, shear force) or compounds (e.g., surfactants and iono-
phores), leading to physical disruption of the plasma membrane
(Bech-Hansen et al., 1976; Callaghan and Riordan, 1995). It was
proposed that high expression of this large polytopic membrane
protein conferred greater fragility to the host cell membrane. However,
the vast majority of observations were gleaned from cell lines selected
for drug resistance and therefore likely to display numerous functional
alterations. In addition, the issue of whether the membrane biophysical
changes were a cause or effect of the resistant phenotype remained
unclear as did the relationship to collateral sensitivity.
Observations that metabolic inhibitors also imparted collateral
sensitivity suggested that bioenergetic metabolism in resistant cells
may provide another therapeutic target (Ferretti et al., 1993; Bentley
et al., 1996; Goda et al., 2002). The metabolic adaptations observed in
cancer cells (e.g., Warburg effect) are now considered a hallmark
feature of oncogenic transformation (Gillies and Gatenby, 2007; Zhao
et al., 2011). Multidrug efflux pumps such as P-gp mediate an ATP-
dependent transport process and sustain a high rate of ATP hydroly-
sis in the presence of substrate. Cancer cells have modified their
metabolic profile to ensure sufficient anabolism to generate biomass
for proliferation. This is achieved by a dampening of mitochondrial
oxidative phosphorylation, with a heavy reliance on glycolysis despite
its lower yield of energy (Bui and Thompson, 2006; Gillies and
Gatenby, 2007). Thus, resistant cancer cells, with ATP-consuming
efflux pumps, may conceivably be more susceptible to conditions of
low energy status.
A significant proportion of established collateral sensitivity
agents is known to be a substrate for transport by P-gp or stimulate
its rate of ATP hydrolysis. A study by Broxterman et al. (1988)
demonstrated that the collateral sensitizing drug verapamil
significantly depleted ATP levels in a drug-resistant cell line. It
has been proposed that depletion of ATP necessitates increased rates
of oxidative phosphorylation in drug-resistant cells and that this
oxidative stress results in an increased production of reactive oxygen
species (e.g., O2
2, H2O2). Increased reactive oxygen species and
concomitant reductions in the antioxidant glutathione were asso-
ciated with apoptosis in drug-resistant CHO cells (Karwatsky et al.,
2003). Conversely, compounds that are known to inhibit ATPase
activity of P-gp (e.g., Tariquidar and PSC833) can diminish the
effectiveness of collateral sensitivity agents. In addition, the extent
of collateral sensitivity is proportional to the expression levels of
P-gp, which may also reflect the strain on ATP levels (Goldsborough
et al., 2011). More systematic characterization of ATP levels and
metabolic fuel utilization in drug-resistant cells is clearly
warranted.
A number of compounds have been demonstrated to elicit collateral
sensitivity and include Tiopronin (Goldsborough et al., 2011),
Desmosdumotin (Nakagawa-Goto et al., 2008), NSC73306 (Hall
et al., 2011), Dp44mT (Whitnall et al., 2006), and sigma-2 receptor
agonists (Niso et al., 2013). These compounds impart collateral
sensitivity; however, their mechanism remains unclear to date.
Although these compounds are too preliminary for clinical applica-
tion, they provide proof-of-principle that targeting this metabolic
“weakness” in drug-resistant cells may provide an important adjunct to
conventional chemotherapy.
Cytotoxic Drug Delivery Using Particles or Polymers
Chemotherapy drugs, particularly the genotoxic class, are un-
fortunately associated with severe and dose-limiting side effects,
particularly in proliferating tissues. Therefore, the emergence of a
drug-resistant phenotype cannot simply be overcome with escalation
of dose. As indicated in preceding sections, the strategy to overcome
resistance by inhibiting the activity of efflux pumps, such as P-gp, is
also fraught with danger. P-gp is expressed at numerous locations in
healthy tissue, and its inhibition will effectively open sanctuary sites
(e.g., central nervous system and testes) to cytotoxic anticancer drugs
(Leslie et al., 2005; de Vries et al., 2007; Robillard et al., 2012; Ke
et al., 2013).
The observation that encapsulating doxorubicin within lipo-
somes could circumvent P-gp–mediated MDR (Thierry et al., 1989;
Sadasivan et al., 1991) provided a degree of cautious optimism.
Clearly, this novel drug delivery route was able to bypass the actions
of P-gp, because liposomal doxorubicin would enter the cells after
endocytic engulfment of the particles rather than diffusion through the
bilayer. This observation was used to formulate the “vacuum cleaner”
hypothesis for the mechanism of P-gp (Higgins and Gottesman, 1992;
Ferté, 2000). Elegant studies with the fluorescent P-gp substrate
calcein-AM were used to demonstrate that drugs do not need to
“enter” the cytoplasm to become translocated by P-gp (Homolya et al.,
1993). A mechanism of translocation whereby P-gp extracts drugs
directly from the lipid milieu (Raviv et al., 1990; Homolya et al.,
1993) gained general acceptance.
The liposomal delivery system may also provide a safe mechanism
for significant dose escalation, because the volume of distribution for
the drug will be modified by restricting diffusion out of the circulatory
system. Clearance from the circulatory system was recognized early
on as a limiting factor for the use of liposome-based systems. The
primary issue is the ability of the reticuloendothelial system to trap and
remove liposomes from the plasma, thereby considerably reducing
residence time in the circulation (Oku and Namba, 1994). The
incorporation of polymers, such as PEG or sialo-gangliosides, reduces
trapping by the reticuloendothelial system (Oku and Namba, 1994;
Gabizon and Martin, 1997). Tumors are widely accepted as a suitable
target for liposomal encapsulation strategies because of their aberrant
vasculature. In particular, the intratumor vasculature is leaky and thus
enables high extravasation of the liposomes.
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A considerable and ongoing level of interest in this strategy re-
mains, although some refinement remains to improve particle stability
and provide targeted delivery of the payload to the tumor.
Encapsulation strategies are now considerably more elaborate
than the early liposomal systems. Modern delivery systems are
referred to as nanoparticles or nanocarriers that feature drugs ad-
sorbed, internalized, conjugated, or chelated to a platform (Hall
et al., 2007; McNeil, 2009; Milane et al., 2011). The platforms
include emulsions (e.g., PEG), liposomes, polymers, colloidal gold,
and nanocrystals; moreover, they frequently contain mixtures of
these. Nanoparticles improve the therapeutic index (LD50/ED50) by
increasing bioavailability (fraction of dose reaching circulation) and
reducing toxicity (Daum et al., 2012). Nanocarriers with encapsu-
lation render the pharmacokinetic profile of a drug to be entirely
dictated by properties of the platform. In addition, the high surface-
to-volume ratios enable high encapsulation or surface adsorption of
the payload drug.
Nanocarriers may be readily configured to contain 1) multiple
payloads (e.g., drug and DNA/RNA), 2) molecules to enable tissue-
specific targeting, and 3) “optical” agents for imaging and tracking.
Strategies to target nanocarriers to tumors make use of the altered
surface protein profile or expression levels for receptors in cancer
cells. For example, folate derivatives (Yang et al., 2011), transferrin
(Bellocq et al., 2003), or epidermal growth factor receptor (EGFR)-
related molecules (El-Sayed et al., 2006; Magadala and Amiji, 2008)
may be surface localized on nanocarriers to facilitate interaction with
their respective receptor targets, which frequently display distinct
expression patterns at the tumor site. The most commonly used
techniques for modern imaging of nanocarriers are positron emission
tomography or single photon emission computed tomography, which
make use of a growing arsenal of radiolabeled compounds (Petersen
et al., 2012). However, optical approaches such as fluorescence,
infrared spectroscopy, and ultrasound are also widely used in ex-
perimental or clinical settings (Kozlowska et al., 2009). Imaging
techniques provide measures of plasma clearance and tumor bio-
availability: the latter a largely overlooked parameter in standard
clinical trial design yet integral in generating an efficacious response.
After internalization of the nanocarrier, the payload must be released
to reach the specific intracellular target. Typically, internalized
particles will enter the endosomal pathway that leads to lysosomal
degradation (Riezman et al., 1997; Wattiaux et al., 2000), which may
result in irretrievable transformation or sequestration of the payload. A
number of strategies have been adopted, including the use of cell-
penetrating peptides (Sarko et al., 2010; Choi et al., 2011) or platforms
containing drug tethers that are destabilized by the acidic intratumoral
microenvironment (Andreev et al., 2010; Gao et al., 2010; Du et al.,
2013).
The use of nanocarriers to circumvent MDR by P-gp has adopted
a number of guises. Lipid-dextran complexes as nanocarriers were
shown to increase the potency of doxorubicin and suppress the
expression of P-gp in resistant cells (Susa et al., 2010). The twofold
effect of these nanocarriers on resistance was achieved using a payload
of high doxorubicin dose and siRNA directed against the mdr1 gene.
Another study using a dual payload strategy (paclitaxel and lonidamine)
also overcame the multidrug-resistant phenotype in cultured cells
(Milane et al., 2011). Paclitaxel is a tubulin-disrupting anticancer
drug, whereas lonidamine is a hexokinase II inhibitor that reduces
glycolytic flux that produces cellular energetic stress. The platform
consisted of a combination of polycaprolactone with PEG and con-
tained an EGFR specific peptide. The latter was included to ensure
targeting to drug-resistant MDR cells, which have been demonstrated
to express elevated levels of EGFR.
Super-hi-magnetization nanocarriers produced with a highly
magnetic Fe3O4 core and a poly-[N-(1-butyric acid)]aniline shell
have also been used to tackle P-gp-mediated MDR (Hua et al.,
2011). The Fe3O4 core acted as a contrast agent to enable tracking of
the nanocarriers using magnetic resonance imaging techniques. High
doxorubicin loading was achieved (271 mg drug per mg nanocarrier)
by virtue of conjugating the drug to the aqueous shell. The
conjugated doxorubicin facilitated high-capacity delivery and
markedly improved thermal stability of the drug. A recent in-
vestigation used platform comprising a copolymer of polystyrene
oxide-polyethylene oxide to target drug-resistant cells expressing
P-gp (Cambón et al., 2013a,b). Intriguingly the copolymer unimers
were able to directly inhibit the activity of P-gp, and the iron oxide-
titanium oxide core enabled magnetic resonance imaging tracking of
the spherical nanocarriers. Doxorubicin was the primary payload and
was bound to the shell via titanium oxide, which was labile in the
acidic pH within a tumor microenvironment. These polymers were
remarkably stable and delivered ~150% more doxorubicin than ob-
served with drug alone.
This exciting area of research has limitless possibilities and
provides the potential for high-dose delivery of anticancer drugs and
P-gp inhibitors (chemical or nucleotide based). The delivery may be
safely tracked using noninvasive procedures and specifically targeted
to the tumor site.
Microparticles as Novel Therapeutic Targets for the Prevention of
MDR
Microparticles (MPs), also known as microvesicles, are enclosed
plasma membrane fragments of size 0.1–1 mm characterized with
phosphatidylserine expression on their surface (Gyorgy et al., 2011).
MPs are typically released by vesiculation from the plasma membrane
of stimulated or preapoptotic eukaryotic cells and had long been
deemed to be inert cell debris (Freyssinet, 2003; Freyssinet and Toti,
2010).
In the last decade however, increasing evidence suggests that MP
plays an essential role in cell-to-cell communications, allowing for cell
regulation and crosstalk without the need for direct cell-to-cell contact.
MPs act as vectors disseminating different biologic information,
depending on their donor cell membrane and cytoplasmic composi-
tion. It is clear that MPs are important intermediates in inflammation,
coagulation, vascular homeostasis, chemotaxis, adhesiveness, and
thrombogenicity of endothelial cells and cells of hematopoietic lineage
(Morel et al., 2004; Hugel et al., 2005). MPs shed from cancer cells
are associated with tumor angiogenesis, evasion of immunosurveil-
lance, cell invasiveness, survival, apoptosis, chemoresistance, and the
hypercoagulable state (Dvorak et al., 1983; Ginestra et al., 1997; Dolo
et al., 1999; Angelucci et al., 2000; Kim et al., 2002; Morel et al.,
2004; Bebawy et al., 2009; Jaiswal et al., 2012b). Moreover, higher
concentrations of systemic MPs are linked to disease progression
and development in cerebral malaria, sepsis, autoimmune disorders,
atherosclerosis, HIV-1, diabetes, and cancer (Horstman and Ahn,
1999; Nomura et al., 2004, 2008; Combes et al., 2006; Bebawy et al.,
2009; Burnier et al., 2009).
The emergence of MDR was long attributed to "genetic alterations"
within the cancer cell after an initial chemotherapeutic insult resulting
in alterations to the cellular apparatus for prosurvival mechanisms.
Bebawy et al. (2009) first reported that MDR can also be acquired in
a non-"genetic manner" through a process of cell-to-cell communica-
tion in the absence of drug exposure. MDR cancer cells were shown to
spontaneously shed MPs from their surface. These MDR-MPs contain
cargo from the donor-resistant cells, in particular, functional resistance
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proteins, which when transferred to a drug-responsive recipient cancer
cell confer MDR within 4 hours (Bebawy et al., 2009; Lu et al., 2013).
This phenomenon has since been shown to occur in vivo (Jaiswal
et al., 2013), whereby these microparticles transfer resistance proteins
deep within the tumor core within 24 hours of MP exposure. This
process also serves to "retemplate" the transcriptional landscape of
recipient cells and in doing so results in the selective dominance of
deleterious traits within the cancer cell population (Jaiswal et al.,
2012a). Furthermore, in addition to the transfer of resistance proteins
mediating MDR, these microparticles effectively sequester anticancer
drugs and reduce the available free drug concentration available to
a tumor mass, hence constituting a parallel resistance pathway (Gong
et al., 2012).
Modulation and/or inhibition of MP formation and release may
provide a novel therapeutic strategy for the prevention of MDR
(Roseblade et al., 2013). A range of inhibitors have demonstrated
promising effects in diminishing MP production by targeting key
players in the formation of MPs. These include compounds that
modulate calpain activation, calcium channels, and other factors that
indirectly stimulate MP production (Roseblade et al., 2013).
Other inhibitors such as ticlopidine, pantethine, cystamine, LMP-
20, or ROCK inhibitors have also been shown to lower MP levels after
treatment (Shouzu et al., 2004; Wassmer et al., 2005; Penet et al.,
2008; Antonyak et al., 2012). Although some of these drugs are
effective in reducing MP production in patients, they were not capable
of bringing down MP levels similar to the healthy control involved in
the same study (Nomura et al., 2005, 2007). Further investigations are
required to identify more effective inhibitors of MP formation and
production, because it would provide a promising treatment strategy in
the management of tumor drug resistance.
Altered Expression of P-gp
The expression of P-gp in normal (i.e., noncancerous) tissues is
regulated by the nuclear orphan receptors namely, the pregnane X,
steroid and xenobiotic, and the constitutive androstane receptors
(Geick et al., 2001; Synold et al., 2001; Xu et al., 2005). These
receptors mediate induction of the protein in response to cellular
needs, typically defined by the presence of potential substrates. In
particular, these two receptor subtypes are targets for a number of
clinically used medications as well as steroid-based metabolites. The
receptors also induce expression of phase I (e.g., cytochrome P450)
and phase II (e.g., glutathione transferase) metabolizing enzymes
(Ekins and Erickson, 2002; Xu et al., 2005; Weiss and Haefeli, 2013),
further reinforcing the functional link between the efflux pumps and
biotransformation pathways.
Expression of P-gp in cancer tissue is a more complex, or
perhaps a more convoluted, regulatory system. There have been
a wide range of factors that regulate P-gp expression, including
hypoxia (via hypoxia inducible factor 1a) (Comerford et al., 2002),
metabolic acidosis (Thews et al., 2010), and metabolic perturbation
such as glucose deprivation (Ledoux et al., 2003) and generation of
reactive oxygen species (Wartenberg et al., 2005). Many of these
factors derive from the hostile intratumor microenvironment and
reflect cell or tissue stress. Moreover, the ability of anticancer
drugs and radiotherapy to alter P-gp expression occurs via a cellular
damage/stress response rather than a classic induction mechanism.
It appears that P-gp is a key “first responder” to chemical or
environmental insult on cancer tissue to remove potentially lethal
compounds. After induction of cellular stress, the precise pathway
to invoke induction of P-gp expression is complex and likely
involves a multitude of cell signaling pathways (Callaghan et al.,
2008; Sui et al., 2012). It is for this reason that an ever increasing
number of investigations have targeted specific kinases in signaling
pathways with a view to modulating P-gp expression and, thus, the
degree of chemoresistance.
The ability of kinases or signaling pathways to regulate P-gp
function and/or expression warrants a discussion of posttranslational
modifications for this transporter. The seminal manuscript that gave
P-gp its name relied on detecting the protein in drug-resistant CHO
cell membranes by virtue of its glycosylation status (Juliano and Ling,
1976). Further studies on its glycosylation status indicated that P-gp
was synthesized as a 140-kDa precursor that was glycosylated over
a 2- to 4-hour period to its fully mature form that migrated as a broad
band at 180 kDa in SDS-PAGE (Richert et al., 1988; Yoshimura et al.,
1989). Two investigations demonstrated that in the drug-resistant
human KB cell line, P-gp was markedly stable, with a half-life greater
than 24 hours (Richert et al., 1988; Yoshimura et al., 1989). In
multidrug-resistant CHO cells, turnover of P-gp was considerably
more rapid, with a stability half-life of 17 6 3 hours (McClean and
Hill, 1993). More recently, it was demonstrated that expression of a
P-gp-EGFP fusion protein (human P-gp isoform) in KB cells displayed
a total half-life of 2.2 days and a surface stability of 3.7 days (Petriz
et al., 2004). It remains unclear why the human and hamster versions of
P-gp display distinct stabilities; moreover, this is not the only reported
difference between the human and rodent isoforms.
It was subsequently demonstrated that the stability of P-gp was
increased by 4- to 6-fold by serum deprivation or growing cells at high
density (Muller et al., 1995), suggesting an involvement of growth
factors in stability. Similarly, the expression of P-gp is cell cycle
dependent, with greatest stability in the G0/G1 phase (Zhang and
Ling, 2000).
What is the “trigger” to alter the stability of membrane-bound P-gp?
The most likely candidate is the phosphorylation status, and the
protein has of numerous PKC consensus motifs within in the linker
region (Chen et al., 1986; Gros et al., 1986). Moreover, it has been
demonstrated that P-gp is phosphorylated by PKC at several of these
motifs within the linker region (Chambers et al., 1993; Orr et al.,
1993). A number of studies examined the phosphorylation status of
P-gp in cell lines selected for drug resistance and suggested that it
played a key role in the resistant phenotype (Marsh and Center, 1987;
Mellado and Horwitz, 1987; Meyers, 1989; Staats et al., 1990).
Subsequently, a number of investigations focused on using chemical
inhibitors of PKC isoforms to reduce the activity or expression of P-gp
and restore drug sensitivity to the cells (Chambers et al., 1990, 1992;
Bates et al., 1992). The inhibitors were highly successful and pointed
to a regulatory role of phosphorylation for P-gp. However, two
manuscripts in the mid-1990s using site-directed mutagenesis of the
PKC motifs in the linker region deflated this strategy (Germann et al.,
1996; Goodfellow et al., 1996). Disruption of the PKC-mediated
phosphorylation status did not alter the ability of P-gp to confer drug
resistance; this was despite clear evidence of an interaction between
the two proteins (Yang et al., 1996). It is now recognized that the
chemical inhibitors of PKC were substrates for transport by P-gp, and
their effects were related to direct inhibition with anticancer drugs for
transport rather than via altered expression (Sato et al., 1990; Germann
et al., 1995; Smith and Zilfou, 1995).
Perhaps unsurprisingly, the strategy to alter P-gp phosphorylation
status to circumvent drug resistance was discontinued. In the ensuing
period a great deal of research has focused on defining the myriad
signaling pathways that control cancer cell growth. Many of these
pathways (e.g., Ras/MAPK, JNK, p38 MAPK, protein kinase A- and
PKC-related proteins, and PI3K) involve cell proliferation status,
mediate apoptotic signaling, or generate the stress response. These
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signaling pathways are known to modulate P-gp expression in cells,
tumor spheroids, and animal models (Chen and Sikic, 2012; Sui et al.,
2012; Breier et al., 2013). In addition, both chemical inhibitors and
silencing strategies (e.g., siRNA) of enzymes within these pathways
have been demonstrated to affect P-gp function. Table 1 provides
a small and selected list (restricted to 2013) of signaling pathway
inhibitors that alter P-gp function in drug-resistant cells.
Unfortunately, the vast majority of these studies have adopted
a similar strategy to those involving PKC in the 1990s, namely that the
reporter assay was based exclusively on measurement of overall
cytotoxicity. On the basis of this previous experience, it may be
argued that mechanistic information will be of paramount importance
in the possibility of reviving this strategy to tackle MDR. Key
parameters include whether 1) the phosphorylation (or other post-
translational modification) status of P-gp, 2) the total cellular
expression level of P-gp, or 3) the cellular localization of P-gp has
been altered. It would also be informative to ascertain whether
novel kinases or phosphatases directly interact with the transporter.
Pharmacological investigations should address whether the chemical
inhibitors of signaling pathways actually modulate P-gp function by
competing with anticancer drugs for the transport process.
Differential Modulation of P-gp
At present, the common strategy of incorporating pharmacological
inhibitors of P-gp in conventional treatment regimens is complicated
with issues of specificity, toxicity, and differential modulation. It
was shown previously that P-gp transport function, and subse-
quently MDR in cancer, is differentially modulated depending on
the drug combination used and the site of interaction within the
plasma membrane bilayer (Bebawy et al., 2001; Huang et al., 2007).
Specifically, modulators appear to have a selective effect depending
on the anticancer drug with which they are combined. For instance, it
has been shown that verapamil reversed resistance of CEM/VLB100
cells to vinblastine and fluorescein-colchicine but not to colchicine
(Bebawy et al., 2001; Huang et al., 2007). In contrast, chlorpromazine
reversed resistance to vinblastine but not to fluorescein-colchicine and
increased the degree of resistance to colchicine (Bebawy et al., 2001;
Huang et al., 2007). Similarly, gypenoside extracts from Gynnostemma
pentaphyllum effectively circumvent colchicine resistance by 15-fold
in P-gp–overexpressed CEM/VLB100 cells, while having no effect
on vinblastine and taxol resistance in the same cells (Huang et al.,
2007). This concept of differential pharmacological modulation has
since been proposed as a cellular mechanism potentially contributing
to the emergence of pharmacoresistant schizophrenia (Bebawy and
Chetty, 2008), supporting the significance and application of these
early findings across different clinical conditions. This evidence pro-
vides us with a strategy for tailoring drug regimens to include MDR
inhibitors according to the specific anticancer drug combinations
used.
Perspectives and Summary
The vast majority of investigations aimed at overcoming drug
resistance conferred by P-gp have employed the mantra of direct in-
hibition of the transporter. Unfortunately, this approach has not yet
reached clinical success due to the complex array of drug toxicity,
altered pharmacokinetics and adverse drug interactions. The current
review has presented a number of alternative approaches to circum-
venting P-gp-mediated MDR. The novel strategies have been
identified through the tireless efforts by researchers to gain a more
complete understanding of this phenotype. These strategies will hope-
fully continue to develop and generate targeted, selective, and nontoxic
strategies to eradicate the presence of MDR in cancer.
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